Adaptive Non Currrent Assets Other from 2010 to 2025

ADPT Stock  USD 7.67  0.55  6.69%   
Adaptive Biotechnologies Non Currrent Assets Other yearly trend continues to be comparatively stable with very little volatility. Non Currrent Assets Other are likely to outpace its year average in 2025. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
2018-12-31
Previous Quarter
5.6 M
Current Value
5.2 M
Quarterly Volatility
1.8 M
 
Covid
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 7.6 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 4.69, Dividend Yield of 0.0 or PTB Ratio of 4.57. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Non Currrent Assets Other Growth Pattern

Below is the plot of the Non Currrent Assets Other of Adaptive Biotechnologies Corp over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Adaptive Biotechnologies' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other10 Years Trend
Slightly volatile
   Non Currrent Assets Other   
       Timeline  

Adaptive Non Currrent Assets Other Regression Statistics

Arithmetic Mean6,263,825
Geometric Mean641,421
Coefficient Of Variation211.49
Mean Deviation8,420,216
Median247,000
Standard Deviation13,247,097
Sample Variance175.5T
Range40.7M
R-Value0.67
Mean Square Error103.7T
R-Squared0.45
Significance0
Slope1,863,171
Total Sum of Squares2632.3T

Adaptive Non Currrent Assets Other History

202540.8 M
202438.8 M
20236.5 M
20224.5 M
2021M
20202.7 M
20192.9 M

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Non Currrent Assets Other38.8 M40.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.